Cwm LLC Purchases 576 Shares of Zoetis Inc. (NYSE:ZTS)

Cwm LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,951 shares of the company’s stock after acquiring an additional 576 shares during the period. Cwm LLC’s holdings in Zoetis were worth $13,609,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC increased its stake in Zoetis by 7.4% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock valued at $16,308,000 after acquiring an additional 6,457 shares during the period. Peak Financial Advisors LLC bought a new position in Zoetis during the fourth quarter valued at about $2,776,000. BLB&B Advisors LLC increased its stake in Zoetis by 1.9% during the third quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock valued at $10,591,000 after acquiring an additional 1,107 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of Zoetis by 10.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after purchasing an additional 17,976 shares during the period. Finally, Ninety One UK Ltd grew its stake in shares of Zoetis by 13.1% in the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock valued at $21,374,000 after purchasing an additional 12,537 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on ZTS. The Goldman Sachs Group upped their price objective on Zoetis from $190.00 to $226.00 and gave the company a “buy” rating in a research note on Wednesday, January 17th. Barclays upped their price objective on Zoetis from $255.00 to $260.00 and gave the company an “overweight” rating in a research note on Wednesday, February 14th. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price objective (down from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Stifel Nicolaus lowered their price objective on Zoetis from $215.00 to $195.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd. Finally, StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and a consensus target price of $221.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total transaction of $159,983.59. Following the completion of the sale, the executive vice president now owns 15,723 shares in the company, valued at approximately $2,725,267.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders have sold 2,209 shares of company stock valued at $371,293. 0.15% of the stock is currently owned by corporate insiders.

Zoetis Stock Down 4.3 %

Shares of ZTS opened at $146.50 on Monday. The company has a market capitalization of $67.00 billion, a P/E ratio of 28.90, a PEG ratio of 2.24 and a beta of 0.85. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.36 and a quick ratio of 2.00. Zoetis Inc. has a one year low of $145.80 and a one year high of $201.92. The business’s 50 day simple moving average is $175.48 and its 200-day simple moving average is $180.15.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The business had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.19 billion. Zoetis had a return on equity of 51.25% and a net margin of 27.43%. The firm’s revenue was up 8.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.15 earnings per share. As a group, sell-side analysts predict that Zoetis Inc. will post 5.79 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. This represents a $1.73 annualized dividend and a yield of 1.18%. The ex-dividend date is Thursday, April 18th. Zoetis’s dividend payout ratio is 34.12%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.